Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Rhea-AI Summary

Protagenic Therapeutics (OTCQB:PTIX) completed a separation from Phytanix on March 17, 2026, returning and cancelling 117,690 merger shares and reducing shares outstanding to 1,810,208 as of March 5, 2026.

The transaction removed >$6.3 million of liabilities (total liabilities cut to ~ $0.5 million), eliminated >$1 million of annualized costs, resolved merger-related litigation, and refocused capital and management on lead asset PT00114 with positive Phase 1 multiple-dose safety data and Phase 2 enrollment planned for 2026.

Positive

• Merger shares returned and cancelled: 117,690 (~6% of Nov 2025 base)
• Total liabilities reduced by > $6.3 million to approximately $0.5 million
• Annualized cost savings exceed $1 million
• PT00114 has positive Phase 1 multiple-dose safety data; Phase 2 planned in 2026

Negative

• Clinical program remains early-stage: only Phase 1 safety data completed to date
• Remaining liabilities of approximately $0.5 million persist as ordinary-course payables

News Market Reaction – PTIX

+10.69%

1 alert

+10.69% News Effect

On the day this news was published, PTIX gained 10.69%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Liabilities removed: more than $6.3 million Liabilities reduced to: approximately $0.5 million Annualized cost savings: more than $1 million +5 more

8 metrics

Liabilities removed more than $6.3 million Phytanix separation; balance sheet cleanup

Liabilities reduced to approximately $0.5 million Post-separation remaining liabilities, mainly trade payables

Annualized cost savings more than $1 million Eliminated Phytanix-related personnel and operating expenses

Shares outstanding (Nov 2025) 1,934,878 shares Common shares outstanding as of November 26, 2025

Returned merger shares 117,690 shares Shares from May 2025 Phytanix transaction returned and cancelled

Shares outstanding (Mar 2026) 1,810,208 shares Common shares outstanding as of March 5, 2026

Liabilities pre-separation approximately $6.8 million Total liabilities before Phytanix unwind

Phase 2 timing 2026 PT00114 Phase 2 enrollment planned for 2026

Market Reality Check

Price: $0.6950 Vol: Volume 2,327 is 0.22x the...

low vol

$0.6950 Last Close

Volume Volume 2,327 is 0.22x the 20-day average of 10,520, indicating limited pre-news trading interest. low

Technical PTIX trades below its 200-day MA of 2.44, at 0.4901, which is 96.57% below its 52-week high of 14.28 and 96.04% above its 52-week low of 0.25.

Peers on Argus

Sector peers show mixed moves: GTBP up 4.99%, SLRX up 18.98%, INDP down 2.23%, S...

1 Up 1 Down

Sector peers show mixed moves: GTBP up 4.99%, SLRX up 18.98%, INDP down 2.23%, SPRC down 0.92%. Momentum scanner flags SLXN up and DRMA down, suggesting no unified biotech rotation tied to this headline.

Historical Context

3 past events · Latest: Mar 10 (Positive)

Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Market upgrade, pipeline	Positive	+16.4%	Upgrade to OTCQB and reiteration of Phase 2 plans for PT00114.
Dec 09	Phase 1 topline data	Positive	-1.8%	Positive Phase 1 multiple-dose safety results for PT00114 in volunteers.
Nov 13	Phase 1 MAD completion	Positive	+9.4%	Completion of enrollment and dosing in Phase 1 MAD study of PT00114.

Pattern Detected

Recent PTIX news tied to clinical milestones and listing changes has more often aligned with positive price moves, though there has been at least one divergence where positive clinical data coincided with a small decline.

Recent Company History

Over the last several months, PTIX has focused on both its listing status and development of lead candidate PT00114. On Nov 13, 2025, completion of enrollment and dosing in the Phase 1 MAD study was followed by a 9.38% gain. Positive topline Phase 1 multiple-dose safety results on Dec 9, 2025 saw a modest -1.82% move. An upgrade to the OTCQB venture market on Mar 10, 2026 coincided with a 16.39% rise. Today’s balance sheet and focus shift continues this trajectory toward centering the story on PT00114.

Market Pulse Summary

The stock surged +10.7% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +10.7% in the session following this news. A strong positive reaction aligns with the company’s shift to a cleaner balance sheet and tighter focus on PT00114. The unwind removed more than $6.3 million of liabilities, cut over $1 million in annualized costs, and reduced the share count to 1,810,208. Historically, PTIX often reacted well to strategic and listing milestones, though one positive clinical update saw a small decline, suggesting enthusiasm can vary as new financing or execution risks emerge.

Key Terms

phase 1, phase 2, multiple-dose, adverse events, +2 more

6 terms

phase 1 medical

"positive multiple-dose Phase 1 safety data and Phase 2 enrollment planned"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"Phase 2 enrollment planned for 2026."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

multiple-dose medical

"positive topline results from the program's Phase 1 multiple-dose study"

A multiple-dose regimen means a medication or treatment is given repeatedly over a period of time rather than as a single one-off dose; studies labeled "multiple-dose" track how the drug builds up, how long it lasts, and whether repeated use causes side effects. For investors, these results reveal real-world safety, effectiveness, dosing convenience and manufacturing needs—factors that influence commercial appeal, regulatory approval chances and ongoing costs, much like testing how a car performs on many trips versus just one.

adverse events medical

"no serious adverse events were observed and all planned cohorts completed"

Adverse events are any harmful or unwanted medical occurrences experienced by people using a drug, device, or undergoing a treatment, whether or not the problem is caused by the product. Think of them as complaints or breakdowns noticed during a trial or after a product is on the market; regulators record and investigate them. Investors care because clusters or serious adverse events can delay approvals, trigger costly studies or recalls, change labeling, and quickly alter a company’s revenue and risk profile.

teneurin c-terminal associated peptide (tcap) medical

"targeting the teneurin C-terminal associated peptide (TCAP) pathway, a novel"

Teneurin C‑terminal associated peptide (TCAP) is a short biological molecule produced from the tail end of teneurin proteins that acts like a messenger in the brain and body, influencing mood, stress responses and cellular energy. Investors care because molecules like TCAP can be targets or leads for new drugs, diagnostics or therapies; discoveries about their effects can change a company’s development plans, clinical trial prospects and potential market value much like finding a new ingredient that changes a recipe’s success.

treatment-resistant depression medical

"studied for treatment-resistant depression, anxiety and related stress disorders."

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

AI-generated analysis. Not financial advice.

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114

NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders, today announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic's capital structure, materially reducing liabilities and sharpens the Company's operating focus on PT00114.

At the common-share level, the separation impact is measurable for shareholders. Protagenic reported 1,934,878 common shares outstanding as of November 26, 2025. Under the separation agreement, all 117,690 common shares issued in connection with the May 2025 transaction were returned to the Company and cancelled. As of March 5, 2026, Protagenic reported 1,810,208 common shares outstanding. The returned merger shares represented approximately 6% of the November 2025 common share base, increasing the ownership percentage represented by each remaining common share.

The separation also removes more than $6.3 million of liabilities from Protagenic's balance sheet, reducing total liabilities from approximately $6.8 million to approximately $0.5 million, while eliminating more than $1mm in annualized costs associated with the Phytanix organization and their operations.. Protagenic expects the remaining approximately $0.5 million of liabilities to consist principally of ordinary-course trade payables associated with ongoing operations.

Key Implications for PTIX Shareholders

• Greater per-share ownership. The 117,690 merger shares returned and cancelled represented approximately 6% of the 1,934,878 common shares outstanding reported as of November 26, 2025. As of March 5, 2026, the Company reported 1,810,208 common shares outstanding.

• Materially cleaner balance sheet. More than $6.3 million of liabilities were removed, reducing total liabilities to approximately $0.5 million, principally ordinary-course payables.

• Leaner cost structure. More than $1 million of annualized personnel and related operating expense tied to the Phytanix organization has been eliminated.

• Capital concentrated on PT00114. Management can now prioritize a first-in-class clinical program with positive multiple-dose Phase 1 safety data and Phase 2 enrollment planned for 2026.

• Reduced transaction overhang. Merger-related litigation has been resolved, governance has been simplified and each company can advance independently.

PT00114, a first-in-class investigational compound targeting the TCAP pathway, is now the Company's primary clinical priority. In December 2025, Protagenic reported positive topline results from the program's Phase 1 multiple-dose study: PT00114 was well tolerated across all dose ranges studied, no serious adverse events were observed and all planned cohorts completed dosing. The Company remains on track to begin Phase 2 enrollment in 2026.

"This separation materially strengthens Protagenic's corporate profile and narrows our execution focus," said Garo Armen, Ph.D., Executive Chairman of Protagenic. "We now have fewer common shares outstanding, a far lighter liability structure and a leaner operating model. Most importantly, we can commit management attention and capital to PT00114, which we believe represents the Company's most important opportunity to create value."

"PT00114 is an especially compelling clinical asset because it is pursuing a differentiated pathway in disorders where unmet need remains substantial," said Bill Nichols, President of Protagenic. "With positive Phase 1 multiple-dose safety data in hand and Phase 2 targeted for 2026, we believe the Company is better positioned to pursue the next stage of development from a cleaner and more focused operating base."

The liability reduction principally reflects the removal of legacy Phytanix notes, payables, derivative obligations and related-party balances from Protagenic's balance sheet. The separation also terminates Phytanix-related employment, consulting and advisory arrangements and simplifies the Company's governance structure.

About PT00114

PT00114 is Protagenic's lead clinical program and a first-in-class investigational compound targeting the teneurin C-terminal associated peptide (TCAP) pathway, a novel mechanism being studied for treatment-resistant depression, anxiety and related stress disorders. The program recently reported positive Phase 1 multiple-dose safety data, including tolerability across all dose ranges studied and no serious adverse events observed. Protagenic is advancing PT00114 toward Phase 2 in 2026.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc. (OTCQB:PTIX) is a clinical-stage biopharmaceutical company focused on developing first-in-class peptide-based treatments for stress-related neuropsychiatric disorders. The Company is headquartered in New York, NY.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the anticipated benefits of the settlement and separation related to the Phytanix transaction, the Company's expected balance sheet and liability position following the transaction, anticipated reductions in annual operating costs, the planned timing of Phase 2 enrollment for PT00114, and the therapeutic potential of PT00114 in treatment-resistant depression, anxiety and related stress disorders. These statements are based on current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those expressed or implied. Factors that could cause such differences include, without limitation, the inherent uncertainty of clinical development, regulatory review and approval processes, the availability of financing, and other risks described in the Company's filings with the Securities and Exchange Commission. Protagenic Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor & Media Contact: Protagenic Therapeutics, Inc. | info@protagenic.com | www.protagenic.com

SOURCE: Protagenic Therapeutics, Inc.

View the original press release on ACCESS Newswire

FAQ

How many shares did Protagenic (PTIX) cancel in the Phytanix separation on March 17, 2026?

Protagenic cancelled 117,690 merger shares, reducing the common share base by about 6%. According to the company, shares outstanding fell to 1,810,208 as of March 5, 2026, from 1,934,878 reported Nov 26, 2025.

What liability reduction did Protagenic (PTIX) report after the Phytanix separation?

The company removed more than $6.3 million of liabilities, cutting total liabilities to ~$0.5 million. According to the company, the remaining liabilities are principally ordinary-course trade payables.

How much annual cost savings did PTIX achieve from the Phytanix separation?

Protagenic eliminated over $1 million in annualized personnel and related operating expenses. According to the company, these savings arise from terminating Phytanix-related employment and consulting arrangements.

What is the status and next step for PT00114 after Protagenic's March 2026 restructuring?

PT00114 is now the company's primary clinical focus with positive Phase 1 multiple-dose safety data. According to the company, Protagenic expects to begin Phase 2 enrollment in 2026.

Does the Phytanix separation resolve litigation and governance issues for PTIX?

Yes; the company says merger-related litigation has been resolved and governance simplified. According to the company, each entity can now advance independently with reduced transaction overhang.

How does the share cancellation affect per-share ownership for PTIX investors?

Cancelling the 117,690 merger shares increased each remaining share's ownership percentage by about 6%. According to the company, this concentrates existing equity among fewer common shares outstanding.